Sugii, Shigeki, Olson, Peter, Sears, Dorothy D., Saberi, Maziyar, Atkins, Annette R., Barish, Grant D., Suk-Hyun Hong, Castro, Glenda L., Yun-Qiang Yin, Nelson, Michael C., Hsiao, Gene, Greaves, David R., Downes, Michael, Yu, Ruth T., Olefsky, Jerrold M., and Evans, Ronald M.
Although peroxisome proliferator-activated receptor gamma (PPARy) agonists such as thiazolidinediones (TZDs) are widely used to treat type 2 diabetes, how its activation in individual tissues contributes to TZD's therapeutic action remains controversial. As TZDs are known to have receptor-independent effects, we sought to establish gain-of- function animal models to delineate the receptor's insulin-sensitizing actions. Unexpectedly, we find that selective activation of PPAR7 in adipocytes, but not in macrophages, is sufficient for whole-body insulin sensitization equivalent to systemic TZD treatment. In addition to improved adipokine, inflammatory, and lipid profiles, PPAR7 activation in mature adipocytes normalizes serum insulin without increased adipogenesis. Co-culture studies indicated that PPARy-activated adipocytes broadly suppress induction of inflammatory cytokines and C-X-C family chemokines in macrophages. Collectively, these data describe an "adipocentric" model in which adipose activation of PPAR7 is sufficient for complete insulin sensitization and suggest a specific application for fat selective PPAR7 modulators in diabetic therapy. [ABSTRACT FROM AUTHOR]